Atosiban Labatec 6.75 mg / 0.9 ml, solution injectable
7680691850011
CH-69185
Injektionslösung
Associated product:
ATOSIBAN Labatec sol inj 6.75 mg/0.9ml 0.9 ml
1 / 3
google
Article details
- Package size
- 1
- Selling units
- 1
- Measure
- Durchstechflasche(n)
- Galenic form
- Injektionslösung
- Galenic group
- Injektion/Infusion
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
6.75 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
7.16 MG | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
0.86 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
Authorization holder
Labatec Pharma SA
1217 Meyrin
Authorization information
- Swissmedic authorization number
- 69185
- Drug name
- Atosiban Labatec, solution injectable / solution à diluer pour perfusion
- Galenic form
- LSIN
- ATC Code
- G02CX01
- Authorization status
- Z
- Dispensing category
- B
- First authorization
- 04/03/2024
- Authorization expiration date
- 03/03/2029
- IT Number
- 09.01.2.
- Domain
- Human medicine
Package details
- Description (FR)
- ATOSIBAN Labatec sol inj 6.75 mg/0.9ml 0.9 ml
- Description (DE)
- ATOSIBAN Labatec Inj Lös 6.75 mg/0.9ml 0.9 ml
- Market launch
- 04/03/2024
- Narcotic (BTM)
- No